Novartis Signs an Option Agreement with Iconic Therapeutics for its Ophthalmology Program

 Novartis Signs an Option Agreement with Iconic Therapeutics for its Ophthalmology Program

Exelixis Signs an Exclusive Option and License Agreement with Iconic Therapeutics for Advancing ADC Program

Shots:

  • Novartis to get an option on Iconic’s ophthalmology program in exchange for an up front payment and equity investment in Iconic
  • Iconic is evaluating its anti-Tissue Factor monoclonal antibody, ICON-4 for the treatment of age-related macular degeneration and plans the onset of clinical studies in 2020
  • Iconic Therapeutics targets Tissue Factor biology to develop new therapies that bind to and antagonize Tissue factor in retinal diseases, cancer and other diseases where Tissue Factor is overexpressed

Click here to­ read full press release/ article | Ref: Iconic Therapeutics | Image: Elmvc

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post